文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

高危APOL1基因型慢性肾脏病患者的临床与遗传特征

Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes.
PubMed 文献 · J Am Soc Nephrol · 2023-02-09

在遗传匹配的队列中,高危APOL1基因型慢性肾脏病患者肾衰竭风险更高(HR=1.58),eGFR下降更快(6.55 vs 3.63 ml/min/1.73 m²/年),肾衰竭时更年轻(45.1 vs 53.6岁),G1/G1基因型风险最高;单基因肾病诊断率更低(2.5% vs 6.7%);炎症小体通路罕见错义变异可能修饰APOL1效应。

要点

  • 高危APOL1基因型CKD患者肾衰竭风险增加(HR=1.58),eGFR下降更快。
  • G1/G1基因型在高危基因型中肾衰竭风险最高。
  • 高危APOL1基因型患者单基因肾病诊断率更低(2.5% vs 6.7%)。

核心结论

  • 在遗传匹配队列中,高危APOL1基因型与肾衰竭风险增加和eGFR下降率更高相关,特定高危基因型间存在分级风险,且单基因肾病发生率更低。
  • 炎症小体通路罕见错义变异可能作为APOL1对肾脏疾病效应的遗传修饰因子。

研究设计与样本

  • 评估携带高危APOL1基因型(N=239)与遗传匹配低危基因型(N=1187)的CKD患者肾衰竭风险和eGFR下降率。
  • 通过外显子测序识别单基因肾病,采用外显子组关联研究及基于基因和基因集的塌陷分析评估APOL1基因型对CKD效应的遗传修饰因子。

主要发现

  • 与遗传祖先匹配的低危APOL1基因型CKD患者相比,高危基因型患者肾衰竭风险更高(风险比[HR]=1.58)。
  • 高危基因型患者eGFR下降幅度更高(6.55 vs 3.63 ml/min/1.73 m²/年)。
  • 高危基因型患者肾衰竭时年龄更年轻(45.1 vs 53.6岁),其中G1/G1基因型风险最高。
  • 高危APOL1基因型CKD患者单基因肾病发生率较低(2.5% vs 6.7%)。
  • 基因集分析发现高危APOL1基因型合并CKD个体中炎症小体通路罕见错义变异富集(比值比=1.90)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: APOL1 high-risk genotypes confer a significant risk of kidney disease, but variability in patient outcomes suggests the presence of modifiers of the APOL1 effect. We show that a diverse population of CKD patients with high-risk APOL1 genotypes have an increased lifetime risk of kidney failure and higher eGFR decline rates, with a graded risk among specific high-risk genotypes. CKD patients with high-risk APOL1 genotypes have a lower diagnostic yield for monogenic kidney disease. Exome sequencing revealed enrichment of rare missense variants within the inflammasome pathway modifying the effect of APOL1 risk genotypes, which may explain some clinical heterogeneity. BACKGROUND: APOL1 genotype has significant effects on kidney disease development and progression that vary among specific causes of kidney disease, suggesting the presence of effect modifiers. METHODS: We assessed the risk of kidney failure and the eGFR decline rate in patients with CKD carrying high-risk ( N =239) and genetically matched low-risk ( N =1187) APOL1 genotypes. Exome sequencing revealed monogenic kidney diseases. Exome-wide association studies and gene-based and gene set-based collapsing analyses evaluated genetic modifiers of the effect of APOL1 genotype on CKD. RESULTS: Compared with genetic ancestry-matched patients with CKD with low-risk APOL1 genotypes, those with high-risk APOL1 genotypes had a higher risk of kidney failure (Hazard Ratio [HR]=1.58), a higher decline in eGFR (6.55 versus 3.63 ml/min/1.73 m 2 /yr), and were younger at time of kidney failure (45.1 versus 53.6 years), with the G1/G1 genotype demonstrating the highest risk. The rate for monogenic kidney disorders was lower among patients with CKD with high-risk APOL1 genotypes (2.5%) compared with those with low-risk genotypes (6.7%). Gene set analysis identified an enrichment of rare missense variants in the inflammasome pathway in individuals with high-risk APOL1 genotypes and CKD (odds ratio=1.90). CONCLUSIONS: In this genetically matched cohort, high-risk APOL1 genotypes were associated with an increased risk of kidney failure and eGFR decline rate, with a graded risk between specific high-risk genotypes and a lower rate of monogenic kidney disease. Rare missense variants in the inflammasome pathway may act as genetic modifiers of APOL1 effect on kidney disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Elliott MD, Marasa M, Cocchi E, et al. Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes. J Am Soc Nephrol. 2023. PMID: 36758113. doi:10.1681/ASN.0000000000000094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。